{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:14:33Z","timestamp":1786986873501,"version":"build-2736575974"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.clinthera.2009.07.005","type":"journal-article","created":{"date-parts":[[2009,8,19]],"date-time":"2009-08-19T04:25:15Z","timestamp":1250655915000},"page":"1360-1373","source":"Crossref","is-referenced-by-count":13,"special_numbering":"P1","title":["A review of tolerability and abuse liability of \u03b3-hydroxybutyric acid for insomnia in patients with schizophrenia"],"prefix":"10.1016","volume":"31","author":[{"given":"Joshua T.","family":"Kantrowitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Citrome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Javitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.07.005_bib1","series-title":"Xyrem (sodium oxybate) oral solution","year":"2008"},{"key":"10.1016\/j.clinthera.2009.07.005_bib2","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1093\/sleep\/30.12.1705","article-title":"Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin [published correction appears in Sleep. 2008;31:table of contents]","volume":"30","author":"Morgenthaler","year":"2007","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2009.07.005_bib3","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1468-1331.2006.01473.x","article-title":"EFNS guidelines on management of narcolepsy","volume":"13","author":"Billiard","year":"2006","journal-title":"Eur J Neurol."},{"key":"10.1016\/j.clinthera.2009.07.005_bib4","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.2174\/138955708786141025","article-title":"Multi-faceted aspects of gamma-hydroxybutyric acid: A neurotransmitter, therapeutic agent and drug of abuse","volume":"8","author":"Castelli","year":"2008","journal-title":"Mini Rev Med Chem."},{"key":"10.1016\/j.clinthera.2009.07.005_bib5","series-title":"Dementia Praecox and Paraphrenia","author":"Kraepelin","year":"1919"},{"key":"10.1016\/j.clinthera.2009.07.005_bib6","series-title":"Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision","year":"2000"},{"key":"10.1016\/j.clinthera.2009.07.005_bib7","unstructured":"Kantrowitz JT, Citrome L, Javitt DC. GABAB receptors, schizophrenia and sleep dysfunction: A review of the relationship and its clinical and therapeutic implications. CNS Drugs. In press."},{"key":"10.1016\/j.clinthera.2009.07.005_bib8","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.neuropharm.2009.01.021","article-title":"GABAB\/NMDA receptor interaction in the regulation of extracellular do-pamine levels in rodent prefrontal cortex and striatum","volume":"56","author":"Balla","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.clinthera.2009.07.005_bib9","series-title":"G'd Up 24\/7: The GHB Addiction Guide","author":"Porrata","year":"2007"},{"key":"10.1016\/j.clinthera.2009.07.005_bib10","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1176\/appi.ps.59.4.384","article-title":"Benzodiazepine use and expenditures for Medicare beneficiaries and the implications of Medicare Part D exclusions","volume":"59","author":"Yang","year":"2008","journal-title":"Psychiatr Serv."},{"key":"10.1016\/j.clinthera.2009.07.005_bib11","article-title":"\u2018Date-rape\u2019 drug linked to a death, 69 poisonings","author":"Anon","year":"1997","journal-title":"Wall Street Journal"},{"key":"10.1016\/j.clinthera.2009.07.005_bib13","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1176\/appi.ajp.164.3.402","article-title":"Schizophrenia and cooccurring substance use disorder","volume":"164","author":"Green","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2009.07.005_bib14","first-page":"9","article-title":"Clinical application of 4-hydroxy-butyrate sodium and 4-butyrolactone in neuropsychiatric patients","volume":"20","author":"Tanaka","year":"1966","journal-title":"Folia Psychiatric Neurol Jpn."},{"key":"10.1016\/j.clinthera.2009.07.005_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-1781(83)90082-3","article-title":"Gamma-hydroxybutyrate in the treatment of schizophrenia","volume":"9","author":"Levy","year":"1983","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.clinthera.2009.07.005_bib16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1055\/s-2007-1019583","article-title":"Gamma-hydroxybutyrate treatment of schizophrenia: A pilot study","volume":"14","author":"Schulz","year":"1981","journal-title":"Pharmacopsychiatria"},{"key":"10.1016\/j.clinthera.2009.07.005_bib18","series-title":"Presented at: 12th International Congress of Schizophrenia Research","article-title":"Open label, pilot study of adjunctive Xyrem (sodium oxybate) for the treatment of schizophrenia and associated sleep disturbances","author":"Kantrowitz","year":"2009"},{"key":"10.1016\/j.clinthera.2009.07.005_bib19_1","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1345\/aph.1G456","article-title":"Sodium oxybate for cataplexy","volume":"40","author":"Lemon","year":"2006","journal-title":"Ann Pharmacother."},{"key":"10.1016\/j.clinthera.2009.07.005_bib19_2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1345\/aph.1G456","article-title":"Sodium oxybate for cataplexy","volume":"40","author":"Lemon","year":"2006","journal-title":"Ann Pharmacother."},{"key":"10.1016\/j.clinthera.2009.07.005_bib20","first-page":"42","article-title":"A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy","volume":"25","year":"2002","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2009.07.005_bib21","first-page":"31","article-title":"A 1 2-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy","volume":"26","year":"2003","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2009.07.005_bib22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.5664\/jcsm.26368","article-title":"A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy","volume":"1","year":"2005","journal-title":"J Clin Sleep Med."},{"key":"10.1016\/j.clinthera.2009.07.005_bib23_1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.5664\/jcsm.26444","article-title":"Problems with latest Xyrem group investigation","volume":"2","author":"Hudgel","year":"2006","journal-title":"J Clin Sleep Med."},{"key":"10.1016\/j.clinthera.2009.07.005_bib23_2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5664\/jcsm.26444","article-title":"Problems with latest Xyrem group investigation","volume":"2","author":"Hudgel","year":"2006","journal-title":"J Clin Sleep Med."},{"key":"10.1016\/j.clinthera.2009.07.005_bib24","first-page":"1070","article-title":"The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia","volume":"30","author":"Scharf","year":"2003","journal-title":"J Rheumatol."},{"key":"10.1016\/j.clinthera.2009.07.005_bib25","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1001\/archneur.65.10.1337","article-title":"Sodium oxybate for excessive daytime sleepiness in Parkinson disease: An open-label polysomnographic study","volume":"65","author":"Ondo","year":"2008","journal-title":"Arch Neurol."},{"key":"10.1016\/j.clinthera.2009.07.005_bib26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0741-8329(99)00093-2","article-title":"Gamma-hydroxybutyric acid and alcohol-related syndromes","volume":"20","author":"Moncini","year":"2000","journal-title":"Alcohol"},{"key":"10.1016\/j.clinthera.2009.07.005_bib27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/alcalc\/37.1.67","article-title":"Double-blind controlled trial of gamma-hydroxybutyrate and clomethiazole in the treatment of alcohol withdrawal","volume":"37","author":"Nimmerrichter","year":"2002","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.clinthera.2009.07.005_bib28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/oxfordjournals.alcalc.a008160","article-title":"An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects","volume":"31","author":"Addolorato","year":"1996","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.clinthera.2009.07.005_bib29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0376-8716(02)00340-X","article-title":"Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: An open randomized comparative study","volume":"70","author":"Caputo","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.clinthera.2009.07.005_bib30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0741-8329(99)00089-0","article-title":"Gamma-hydroxybutyric acid in the treatment of alcohol and heroin dependence","volume":"20","author":"Gallimberti","year":"2000","journal-title":"Alcohol"},{"key":"10.1016\/j.clinthera.2009.07.005_bib31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1358\/dot.2008.44.3.1162240","article-title":"Sodium oxybate: Efficacy, safety and tolerability in the treatment of narcolepsy with or without cataplexy","volume":"44","author":"Owen","year":"2008","journal-title":"Drugs Today (Barc)."},{"key":"10.1016\/j.clinthera.2009.07.005_bib32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2174\/157488606775252647","article-title":"The clinical development of gamma-hydroxybutyrate (GHB)","volume":"1","author":"Wedin","year":"2006","journal-title":"Curr Drug Saf."},{"key":"10.1016\/j.clinthera.2009.07.005_bib33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/15563650802022839","article-title":"Area-level socioeconomic status in relation to outcomes in gamma-hydroxybutyrate intoxication","volume":"47","author":"Anderson","year":"2008","journal-title":"Clin Toxicol (Phila)."},{"key":"10.1016\/j.clinthera.2009.07.005_bib34","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/00952990701312316","article-title":"High-risk behaviors and hospitalizations among gamma hydroxybutyrate (GHB) users","volume":"33","author":"Kim","year":"2007","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1016\/j.clinthera.2009.07.005_bib35","first-page":"380","article-title":"Acute poisoning from gamma-hydroxybutyrate in California","volume":"156","author":"Chin","year":"1992","journal-title":"West J Med."},{"key":"10.1016\/j.clinthera.2009.07.005_bib36","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0196-0644(98)70230-6","article-title":"Clinical course of gamma-hydroxybutyrate overdose","volume":"31","author":"Chin","year":"1998","journal-title":"Ann Emerg Med."},{"key":"10.1016\/j.clinthera.2009.07.005_bib37","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/0269881105049041","article-title":"Gamma hydroxy butyrate abuse and dependency","volume":"19","author":"Gonzalez","year":"2005","journal-title":"J Psychopharmacol."},{"key":"10.1016\/j.clinthera.2009.07.005_bib38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0140-6736(74)91639-0","article-title":"Assessment of coma and impaired consciousness. A practical scale","volume":"2","author":"Teasdale","year":"1974","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2009.07.005_bib39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1081\/CLT-120004400","article-title":"Trends in illicit drug emergencies: The emerging role of gamma-hydroxybutyrate","volume":"40","author":"Mir\u00f3","year":"2002","journal-title":"J Toxicol Clin Toxicol."},{"key":"10.1016\/j.clinthera.2009.07.005_bib40","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.drugalcdep.2005.07.010","article-title":"Clinical features of gamma-hydroxybutyrate and gamma-butyrolactone toxicity and concomitant drug and alcohol use","volume":"81","author":"Liechti","year":"2006","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.clinthera.2009.07.005_bib41","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/15563650701263633","article-title":"High mortality rates among GHB abusers in Western Sweden","volume":"46","author":"Knudsen","year":"2008","journal-title":"Clin Toxicol (Phila)."},{"key":"10.1016\/j.clinthera.2009.07.005_bib42","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/15563650701365818","article-title":"Abrupt awakening phenomenon associated with gamma-hydroxybutyrate use: A case series","volume":"45","author":"Van Sassenbroeck","year":"2007","journal-title":"Clin Toxicol (Phila)."},{"key":"10.1016\/j.clinthera.2009.07.005_bib43","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1017\/S1481803500010034","article-title":"Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: A case report and systematic review","volume":"10","author":"Wojtowicz","year":"2008","journal-title":"CJEM."},{"key":"10.1016\/j.clinthera.2009.07.005_bib44","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0002-9343(99)00468-4","article-title":"Gamma-hydroxybutyrate associated deaths","volume":"108","author":"Timby","year":"2000","journal-title":"Am J Med."},{"key":"10.1016\/j.clinthera.2009.07.005_bib45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0379-0738(03)00044-6","article-title":"Forensic cases involving the use of GHB in the Netherlands","volume":"133","author":"Bosman","year":"2003","journal-title":"Forensic Sci Int."},{"key":"10.1016\/j.clinthera.2009.07.005_bib46","doi-asserted-by":"crossref","first-page":"310","DOI":"10.5694\/j.1326-5377.2004.tb06295.x","article-title":"Fatalities associated with the use of gamma-hydroxybutyrate and its analogues in Australasia","volume":"181","author":"Caldicott","year":"2004","journal-title":"Med J Aust."},{"key":"10.1016\/j.clinthera.2009.07.005_bib47","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/jat\/31.9.566","article-title":"Gamma-hydroxybutyrate concentrations in the blood of impaired drivers, users of illicit drugs, and medical examiner cases","volume":"31","author":"Jones","year":"2007","journal-title":"J Anal Toxicol."},{"key":"10.1016\/j.clinthera.2009.07.005_bib48","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/FTD.0b013e3181898c2e","article-title":"Intoxications due to ingestion of gamma-butyrolactone: Organ distribution of gamma-hydroxybutyric acid and gamma-butyrolactone","volume":"30","author":"Lenz","year":"2008","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.clinthera.2009.07.005_bib49","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/FTD.0b013e3180307e5e","article-title":"Disposition of gamma-hydroxybutyric acid in conventional and nonconventional biologic fluids after single drug administration: Issues in methodology and drug monitoring","volume":"29","author":"Abanades","year":"2007","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.clinthera.2009.07.005_bib50","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2105\/AJPH.82.1.128-a","article-title":"GHB use in South Carolina","volume":"82","author":"Luby","year":"1992","journal-title":"Am J Public Health."},{"key":"10.1016\/j.clinthera.2009.07.005_bib51","first-page":"861","article-title":"Multistate outbreak of poisonings associated with illicit use of gamma hy-droxy butyrate","volume":"39","year":"1990","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"10.1016\/j.clinthera.2009.07.005_bib52","article-title":"Epidemiologic notes and reports multistate outbreak of poisonings associated with illicit use of gamma hydroxy butyrate","year":"1990","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.clinthera.2009.07.005_bib53","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.drugalcdep.2007.07.009","article-title":"Use, function, and subjective experiences of gamma-hydroxybutyrate (GHB)","volume":"92","author":"Sumnall","year":"2008","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.clinthera.2009.07.005_bib54","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0741-8329(99)00090-7","article-title":"Abuse and therapeutic potential of gamma-hydroxybutyric acid","volume":"20","author":"Galloway","year":"2000","journal-title":"Alcohol."},{"key":"10.1016\/j.clinthera.2009.07.005_bib55","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/02791072.2008.10400639","article-title":"Gamma hydroxybutyrate: An ethnographic study of recreational use and abuse","volume":"40","author":"Lee","year":"2008","journal-title":"J Psychoactive Drugs."},{"key":"10.1016\/j.clinthera.2009.07.005_bib56","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1081\/JA-200066866","article-title":"Patterns of simultaneous polysubstance use in Canadian rave attendees","volume":"40","author":"Barrett","year":"2005","journal-title":"Subst Use Misuse."},{"key":"10.1016\/j.clinthera.2009.07.005_bib57","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.addbeh.2006.01.009","article-title":"GHB use among gay and bisexual men","volume":"31","author":"Halkitis","year":"2006","journal-title":"Addict Behav."},{"key":"10.1016\/j.clinthera.2009.07.005_bib58","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/jat\/23.3.141","article-title":"Prevalence of drugs used in cases of alleged sexual assault","volume":"23","author":"ElSohly","year":"1999","journal-title":"J Anal Toxicol."},{"key":"10.1016\/j.clinthera.2009.07.005_bib59","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jcfm.2005.03.009","article-title":"Toxicological findings in cases of alleged drug-facilitated sexual assault in the United Kingdom over a 3-year period","volume":"12","author":"Scott-Ham","year":"2005","journal-title":"J Clin Forensic Med."},{"key":"10.1016\/j.clinthera.2009.07.005_bib60","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/1524838008320221","article-title":"The involvement of drugs and alcohol in drug-facilitated sexual assault: A systematic review of the evidence","volume":"9","author":"Beynon","year":"2008","journal-title":"Trauma Violence Abuse."},{"key":"10.1016\/j.clinthera.2009.07.005_bib61","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/jat\/30.2.98","article-title":"A comprehensive study on the variations in urinary concentrations of endogenous gamma-hydroxybutyrate (GHB)","volume":"30","author":"LeBeau","year":"2006","journal-title":"J Anal Toxicol."},{"key":"10.1016\/j.clinthera.2009.07.005_bib62","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.annemergmed.2005.10.012","article-title":"Trends in gamma-hydroxybutyrate (GHB) and related drug intoxication: 1999 to 2003","volume":"47","author":"Anderson","year":"2006","journal-title":"Ann Emerg Med."},{"key":"10.1016\/j.clinthera.2009.07.005_bib63","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/qjmed\/hcm117","article-title":"Medical and legal confusion surrounding gamma-hydroxybutyrate (GHB) and its precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4BD)","volume":"101","author":"Wood","year":"2008","journal-title":"QJM."},{"key":"10.1016\/j.clinthera.2009.07.005_bib64","doi-asserted-by":"crossref","first-page":"709","DOI":"10.5694\/j.1326-5377.2008.tb01851.x","article-title":"Patterns and incidence of gamma-hydroxybutyrate (GHB)-related ambulance attendances in Melbourne, Victoria","volume":"188","author":"Dietze","year":"2008","journal-title":"Med J Aust."},{"key":"10.1016\/j.clinthera.2009.07.005_bib65","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.drugpo.2007.08.007","article-title":"The epidemiology of GHB and ketamine use in an Australian household survey","volume":"19","author":"Degenhardt","year":"2008","journal-title":"Int J Drug Policy"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2009.07.005_bib66","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S0376-8716(03)00098-X","article-title":"Principles of initial experimental drug abuse liability assessment in humans","volume":"70","author":"Griffiths","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.clinthera.2009.07.005_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0376-8716(00)00191-5","article-title":"GHB: A new and novel drug of abuse","volume":"63","author":"Nicholson","year":"2001","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.clinthera.2009.07.005_bib68","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.pbb.2008.02.016","article-title":"Differentiating the discriminative stimulus effects of gamma-hydroxybutyrate and ethanol in a three-choice drug discrimination procedure in rats","volume":"89","author":"Baker","year":"2008","journal-title":"Pharmacol Biochem Behav."},{"key":"10.1016\/j.clinthera.2009.07.005_bib69","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002130050092","article-title":"Evaluation of the discriminative stimulus and reinforcing effects of gamma-hydroxybutyrate (GHB)","volume":"127","author":"Beardsley","year":"1996","journal-title":"Psychopharmacolology (Berl)."},{"key":"10.1016\/j.clinthera.2009.07.005_bib70","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0376-8716(98)00153-7","article-title":"Evaluation of the reinforcing and discriminative stimulus effects of gamma-hydroxybutyrate in rhesus monkeys","volume":"54","author":"Woolverton","year":"1999","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.clinthera.2009.07.005_bib71","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0014-2999(03)01486-9","article-title":"Evaluation of the reinforcing and discriminative stimulus effects of 1,4-butanediol and gamma-butyrolactone in rhesus monkeys","volume":"466","author":"McMahon","year":"2003","journal-title":"Eur J Pharmacol."},{"key":"10.1016\/j.clinthera.2009.07.005_bib72","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/FBP.0b013e328308f20d","article-title":"Gamma-hydroxybutyric acid in male and female cynomolgus monkeys trained to discriminate 1.0 or 2.0 g\/kg ethanol","volume":"19","author":"Helms","year":"2008","journal-title":"Behav Pharmacol."},{"key":"10.1016\/j.clinthera.2009.07.005_bib73","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00213-007-0809-9","article-title":"Modification of ethanol's reinforcing effectiveness in rhesus monkeys by cocaine, flunitrazepam, or gamma-hydroxybutyrate","volume":"193","author":"Winger","year":"2007","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.clinthera.2009.07.005_bib74","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/jcp.0b013e31815a2542","article-title":"Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users","volume":"27","author":"Abanades","year":"2007","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.clinthera.2009.07.005_bib75","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0740-5472(96)00157-2","article-title":"Effects of gamma-hydroxybutyric acid (GHB) in opioid-dependent patients","volume":"14","author":"Rosen","year":"1997","journal-title":"J Subst Abuse Treat."},{"key":"10.1016\/j.clinthera.2009.07.005_bib76","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1038\/sj.npp.1301146","article-title":"Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB","volume":"31","author":"Carter","year":"2006","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.clinthera.2009.07.005_bib77","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/bja\/43.2.113","article-title":"Effect of methohexitone, diazepam and sodium 4-hydroxybutyrate on short-term memory","volume":"43","author":"Grove-White","year":"1971","journal-title":"Br J Anaesth."},{"key":"10.1016\/j.clinthera.2009.07.005_bib78","first-page":"236","article-title":"Actions and interactions with alcohol of drugs on psychomotor skills: Comparison of diazepam and gamma-hydroxybutyric acid","volume":"234","author":"Mattila","year":"1978","journal-title":"Arch Int Pharmacodyn Ther."},{"key":"10.1016\/j.clinthera.2009.07.005_bib79","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s002280050560","article-title":"Effects of single dose of gamma-hydroxybutyric acid and lorazepam on psychomotor performance and subjective feelings in healthy volunteers","volume":"54","author":"Ferrara","year":"1999","journal-title":"Eur J Clin Pharmacol."},{"issue":"Suppl 9","key":"10.1016\/j.clinthera.2009.07.005_bib80","first-page":"31","article-title":"Relative abuse liability of hypnotic drugs: A conceptual framework and algorithm for differentiating among compounds","volume":"66","author":"Griffiths","year":"2005","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.clinthera.2009.07.005_bib81","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/sleep\/9.1.285","article-title":"Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings","volume":"9","author":"Mamelak","year":"1986","journal-title":"Sleep."},{"key":"10.1016\/j.clinthera.2009.07.005_bib82","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0006-3223(89)90048-6","article-title":"Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: Doubleblind subjective measures","volume":"26","author":"Scrima","year":"1989","journal-title":"Biol Psychiatry."},{"key":"10.1016\/j.clinthera.2009.07.005_bib83","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/sleep\/27.7.1327","article-title":"A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy","volume":"27","author":"Mamelak","year":"2004","journal-title":"Sleep."},{"key":"10.1016\/j.clinthera.2009.07.005_bib84","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/sleep\/16.3.216","article-title":"Gammahydroxybutyrate and narcolepsy: A double-blind placebo-controlled study","volume":"16","author":"Lammers","year":"1993","journal-title":"Sleep."},{"key":"10.1016\/j.clinthera.2009.07.005_bib85","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1081\/CLT-120019128","article-title":"The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms","volume":"41","year":"2003","journal-title":"J Toxicol Clin Toxicol."},{"key":"10.1016\/j.clinthera.2009.07.005_bib86","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.pop.2005.02.012","article-title":"Narcolepsy and disorders of excessive somnolence","volume":"32","author":"Dyken","year":"2005","journal-title":"Prim Care."},{"key":"10.1016\/j.clinthera.2009.07.005_bib87","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0741-8329(99)00085-3","article-title":"Safety and tolerability of gamma-hydroxybutyric acid in the treatment of alcohol-dependent patients","volume":"20","author":"Begh\u00e8","year":"2000","journal-title":"Alcohol."},{"key":"10.1016\/j.clinthera.2009.07.005_bib88","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00002826-199901000-00011","article-title":"A case of gamma-hydroxybutyric acid withdrawal syndrome during alcohol addiction treatment: Utility of diazepam administration","volume":"22","author":"Addolorato","year":"1999","journal-title":"Clin Neuropharmacol."},{"key":"10.1016\/j.clinthera.2009.07.005_bib89","unstructured":"Caputo F, Francini S, Stoppo M, et al. Incidence of craving for and abuse of gamma-hydroxybutyric acid (GHB) in different populations of treated alcoholics: An open comparative study [published online ahead of print July 17, 2008]. J Psychopharmacol."},{"key":"10.1016\/j.clinthera.2009.07.005_bib90","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1176\/ajp.2007.164.3.402","article-title":"Schizophrenia and co-occurring substance use disorder","volume":"164","author":"Green","year":"2007","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.clinthera.2009.07.005_bib91","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/01.jcp.0000237944.57893.28","article-title":"Gamma-hydroxybutyrate and ethanol effects and interactions in humans","volume":"26","author":"Thai","year":"2006","journal-title":"J Clin Psychopharmacol."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809002045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809002045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T10:42:27Z","timestamp":1590057747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291809002045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":91,"alternative-id":["S0149291809002045"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.07.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}